Lexeo Therapeutics, INC Schedule 13G passive stakes

D1 Capital Partners L.P. and Daniel Sundheim have filed an amended Schedule 13G, reporting a 2.9% beneficial ownership stake in Lexeo Therapeutics, Inc.

Janus Henderson Group plc and its affiliate have reported a combined beneficial ownership of 13.7% in LEXEO Therapeutics, Inc., totaling 4,557,920 common shares as of March 31, 2025.

Mizuho Financial Group, Inc. has filed an amended Schedule 13G, revealing a 6.6% beneficial ownership stake in Lexeo Therapeutics, Inc. as of March 31, 2025.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has filed an amended Schedule 13G disclosing a beneficial ownership of 0.7% in Lexeo Therapeutics, Inc.'s common stock.

Millennium Management LLC and its affiliates have disclosed a passive beneficial ownership of 5.8% in Lexeo Therapeutics, Inc., totaling 1,933,379 shares of common stock.

Eventide Asset Management, LLC, along with Finny Kuruvilla and Robin C. John, have disclosed a combined beneficial ownership of 3.73% in Lexeo Therapeutics, Inc. common stock as of December 31, 2024.

Janus Henderson Group plc and its affiliates have disclosed a beneficial ownership of 13.1% of Lexeo Therapeutics, Inc.'s common stock as of December 31, 2024, through a Schedule 13G Amendment No. 3 filing.

Omega Fund VI and its affiliates have disclosed a passive beneficial ownership of 3.6% in Lexeo Therapeutics, Inc., holding 1,184,636 shares of common stock as of December 31, 2024.

Mizuho Financial Group, Inc. has filed a Schedule 13G, revealing a 5.8% beneficial ownership stake in Lexeo Therapeutics, Inc. as of December 31, 2024.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has disclosed a 6.68% beneficial ownership stake in Lexeo Therapeutics, Inc., holding 2,209,615 shares of common stock as of December 31, 2024.

BlackRock, Inc. has filed a Schedule 13G, revealing a passive beneficial ownership of 5.5% of Lexeo Therapeutics, Inc.'s common stock as of December 31, 2024.